enGene Therapeutics Inc. (ENGN)
Biological Products, (No Diagnostic Substances)
Latest Price
$1.89
TTM P/E
7.00
Normalized P/E
0.05
Div Yield
--
Book Value
3.30
P/B Ratio
0.57
Valuation metrics
adjust assumptions →EPS: $2.29
Book value / share: $3.22
Formula: √(22.5 × EPS × BVPS)
Graham Number
$12.89
+582% upside
Institutional Ownership
55.9% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BML Capital Management, LLC | 6.67M | $11.0M | 9.96% | -- | 2026-06-30 |
| Siren, L.L.C. | 6.26M | $10.0M | 9.34% | -- | 2026-06-30 |
| PERCEPTIVE ADVISORS LLC | 4.82M | $8.0M | 7.20% | -- | 2026-06-30 |
| AMERIPRISE FINANCIAL INC | 2.68M | $4.0M | 3.99% | -- | 2026-06-30 |
| Nextech Invest Ltd. | 2.32M | $4.0M | 3.47% | -- | 2026-06-30 |
| ADAR1 Capital Management, LLC | 2.10M | $3.0M | 3.14% | -- | 2026-06-30 |
| Vestal Point Capital, LP | 1.67M | $2.0M | 2.49% | -- | 2026-06-30 |
| ACORN CAPITAL ADVISORS, LLC | 1.27M | $2.0M | 1.90% | -- | 2026-06-30 |
| Peapod Lane Capital LLC | 1.10M | $1.0M | 1.65% | -- | 2026-06-30 |
| Balyasny Asset Management L.P. | 1.01M | $1.0M | 1.50% | -- | 2026-06-30 |